Regeneron, Mammoth Partner To Pursue Next-Generation CRISPR-Based Gene Editing For Multiple Diseases; Mammoth To Receive $100M Total Upfront Payment And Equity Investment
Regeneron, Mammoth Partner To Pursue Next-Generation CRISPR-Based Gene Editing For Multiple Diseases; Mammoth To Receive $100M Total Upfront Payment And Equity Investment
Regeneron 與 Mammoth 合作開發下一代基於 CRISPR 的多種疾病基因編輯；Mammoth 將獲得總計 1 億美元的預付款和股權投資
Under the terms of the agreement, Mammoth will receive $100 million inclusive of $95 million in equity investment at signing, and an upfront payment, and is eligible to receive up to $370 million per target in development, regulatory and commercial milestone payments, and royalty rates ranging from single digits to mid-teens on future net sales of all collaboration products.
根據協議條款，Mammoth將在簽署時獲得1億美元，其中包括9500萬美元的股權投資和預付款，並且有資格獲得每個目標最高3.7億美元的開發、監管和商業里程碑付款，以及所有協作產品未來淨銷售額的特許權使用費率從個位數到十幾歲不等。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。